CompletedNCT00483548
Ziprasidone or placebo added to a mood stabilizer for bipolarity depression
About this title
Read the official source —Medication studyAges 18+Multiple countries
Understand this study
Who was this study for?
This study was for people with bipolarity. Listed age limits: from 18 years. Other eligibility criteria applied.
- Listed locations
- Chandler and 69 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateOctober 2007
- Recruitment status
- Completed
- Enrollment listed in the registry
- 298
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Australia, India
- Age range
- Over 18 Years
- Official registry ID
- NCT00483548
- Official title
Show the full official title
A Six-Week, Double-Blind, Multicenter, Placebo Controlled Study Evaluating The Efficacy And Safety Of Flexible Doses Of Oral Ziprasidone As Add-On, Adjunctive Therapy With Lithium, Valproate Or Lamotrigine In Bipolar I Depression
Get this study by email
Recruitment & locations
CompletedChandler, United States · Litchfield Park, United States · Little Rock, United States
59 more locations
- Springdale, United States
- Costa Mesa, United States
- Oceanside, United States
- San Diego, United States
- Torrance, United States
- Boca Raton, United States
- Jacksonville, United States
- Orlando, United States
- Sanford, United States
- St. Petersburg, United States
- West Palm Beach, United States
- Chicago, United States
- Skokie, United States
- Greenwood, United States
- Indianapolis, United States
- Topeka, United States
- Wichita, United States
- Lake Charles, United States
- Rockville, United States
- Boston, United States
- Watertown, United States
- Clinton Township, United States
- Saint Charles, United States
- St Louis, United States
- Lincoln, United States
- Nashua, United States
- Cherry Hill, United States
- Clementon, United States
- Brooklyn, United States
- Glen Oaks, United States
- New York, United States
- Olean, United States
- Rochester, United States
- Staten Island, United States
- Chapel Hill, United States
- Cincinnati, United States
- Columbus, United States
- Dayton, United States
- Oklahoma City, United States
- Portland, United States
- Philadelphia, United States
- Memphis, United States
- Austin, United States
- Houston, United States
- Lake Jackson, United States
- Charlottesville, United States
- Kirkland, United States
- Richland, United States
- Seattle, United States
- Brown Deer, United States
- Westmead, Australia
- Everton Park, Australia
- Spring Hill, Australia
- Richmond, Australia
- Ellisbridge, India
- Ahmedabad, India
- Aurangabad, India
- Pune, India
- Delhi, India
Questions about this study
Who is behind this study?
The study sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Did this study involve medication?
Yes. The study involved medication, including Ziprasidone and Placebo.
Who was this study for?
This study was for people with bipolarity. Listed age limits: from 18 years. Other eligibility criteria applied.
